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Reports in the last decade have suggested that the role of platelets in atherosclerosis
and its thrombotic complications may be mediated, in part, by local secretion of
platelet-derived microvesicles (pMVs), small cell blebs released during the platelet
activation process. MVs are the most abundant cell-derived microvesicle subtype in
the circulation. High concentrations of circulating MVs have been reported in patients
with atherosclerosis, acute vascular syndromes, and/or diabetes mellitus, suggesting a
potential correlation between the quantity of microvesicles and the clinical severity of
the atherosclerotic disease. pMVs are considered to be biomarkers of disease but new
information indicates that pMVs are also involved in signaling functions. pMVs evoke or
promote haemostatic and inflammatory responses, neovascularization, cell survival, and
apoptosis, processes involved in the pathophysiology of cardiovascular disease. This
review is focused on the complex cross-talk between platelet-derived microvesicles,
inflammatory cells and vascular elements and their relevance in the development of the
atherosclerotic disease and its clinical outcomes, providing an updated state-of-the art
of pMV involvement in atherothrombosis and pMV potential use as therapeutic agent
influencing cardiovascular biomedicine in the future.
Keywords: atherosclerosis, cardiovascular diseases, cell-derived microvesicles, inflammation, platelets,
thrombosis
INTRODUCTION
Cardiovascular diseases (CVD) result in more than 19 million deaths annually and coronary
heart disease (CHD) accounts for the majority of this death toll. In most cases, atherosclerosis
and thrombosis associated with unstable plaques are the major cause for cardiovascular events
(CVEs) including acute coronary syndromes (ACS) and stroke (van der Wal and Becker, 1999).
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Atherosclerosis is a systemic disease that starts early in
life, asymptomatically progressing though adulthood, until
clinically manifested. Indeed, large numbers of subjects who
die suddenly of CHD are apparently healthy and had no
previous symptoms (Mujica et al., 2010). Atherothrombosis
is regulated by both genetic and environmental factors (e.g.,
dyslipidemia, hypertension, smoking, diabetes, and obesity;
Marenberg et al., 1994; Palomo et al., 2006). The development
of atherosclerotic lesions result from a complex interplay
between circulating factors and various cell types in the
vessel wall, which leads to the accumulation of lipids in
the subendothelial space and a complex process of chronic
inflammation, mainly characterized by endothelial dysfunction,
leukocyte infiltration, and platelet activation (van der Wal et al.,
1994; Nishijima et al., 2004). Indeed, platelet activation and
subsequent platelet aggregation processes play an essential role
in the development of atherosclerosis, possibly through a vast
amount of molecules released upon platelet activation (Palomo
et al., 2008). Interestingly, increasing evidence support the view
that the role of platelets in atherosclerosis and its thrombotic
complications may be mediated, in part, by local secretion of
molecular effectors embedded or packed into microvesicles from
the platelet surface.
Circulating microvesicles (cMVs) may participate in
haemostatic and inflammatory responses, neovascularization,
cell survival, and apoptosis, processes which are involved in
atherothrombosis (Aatonen et al., 2012). Thus, increased levels
of cMVs derived from platelets (pMVs), erythrocytes (ErMVs),
leukocyte (LMVs), and endothelial cells (eMVs) are associated
with individual metabolic abnormalities caused by metabolic
syndrome and oxidative stress (Ueba et al., 2008; Helal et al.,
2011). ErMVs, LMVs, and eMVs seem to be more abundant in
human atherosclerotic plaques than in plasma (Leroyer et al.,
2007). High amounts of these plaque MVs result from apoptotic
leukocytes within vulnerable plaques. In contrast, MVs of platelet
origin are the most abundant in blood (Rank et al., 2010).
Circulating MVs are found in the plasma of healthy subjects
(Horstman and Ahn, 1999; Berckmans et al., 2001; Caby et al.,
2005; Toth et al., 2007; Grant et al., 2011; Herring et al., 2013)
although their relative concentrations are determined by the
pathophysiological context. Background levels of circulating
pMVs in the absence of disease likely originate from aging
platelets in the absence of activation (Cauwenberghs et al., 2006).
The local release of MVs from platelets at the site of platelet plug
formation indicates a possible role of pMVs in the haemostatic
response in vivo (Lubsczyk et al., 2010). pMV membrane is
a composite of the platelet plasma- and granule membranes
(Biro et al., 2005) and have procoagulant properties which
lead to thrombin generation. Such procoagulant activity (PCA)
relies on the exposure of membrane anionic phospholipids
that enable the assembly of coagulation complexes at the MV
surface, and on the eventual thrombin formation (Sinauridze
et al., 2007). Besides the well-known role of platelet-derived
MVs in coagulation, thrombosis, and haemostasis, pMVs have
been involved in a variety of processes such as wound healing,
inflammation, CVD, diabetes, arthritis, tissue regeneration, and
cancer.
This review summarizes and highlights the latest findings of
the complex cross-talk between platelet-derived microvesicles,
inflammatory cells, and vascular elements, and provides
novel insight and understanding in the development of the
atherosclerotic and thrombotic disease as well as potential
clinical application of pMVs in diagnosis and therapy.
Types of Microvesicles
All blood cells are able to release small membrane bound vesicles.
Extracellular vesicles (EVs) are a heterogeneous population of
membrane-coated microvesicles released by several cell types
upon activation or apoptosis (Azevedo et al., 2007), and include
plasma membrane-derived microparticles or microvesicles,
multivesicular body-derived exosomes, and apoptotic bodies.
These different types of EVs vary in size, and in phospholipid,
nucleic acid, and protein composition (VanWijk et al., 2003).
Microparticles or microvesicles, which directly originate from
the membrane surface, are characterized by phosphatidylserine
(PS) exposure and are generally referred to be between 0.1 and
1.0 µm of diameter (Wiedmer et al., 1990). MVs, with densities
between 1.04 and 1.07 g/mL, are of irregular shape and very
heterogeneous in size. In contrast to MVs, exosomes (20–100 nm)
are cup-shaped vesicles released from exocytosis of endocytic
multivesicular bodies, with a density of 1.10–1.18 g/mL, and the
distinction between both types of vesicles is complex due to an
overlap in their molecular properties and sizes. Exosomes were
first described in platelets, in which the differentiation with MVs
is complex because of α-granules, and in general form a more
homogenous population than MVs, both by size and molecular
content. Thus, multivesicular bodies, the source of exosomes, are
also considered to be pre-stages of α-granules (van Nispen tot
Pannerden et al., 2010), which may then liberate exosomes on
fusion with the plasma membrane. However, several α-granule-
derived molecules are also present on pMVs. Moreover, the
common exosomal marker tetraspanin CD63 is not only enriched
in the platelet-derived exosomes, but it is also present on pMVs
(van der Zee et al., 2006) and, in its turn, many common pMV
proteins are detected on subsets of platelet exosomes (Heijnen
et al., 1999). Apoptotic bodies, remnants of dead cells in the
process of their shrinkage and elimination tend to be larger
than MVs, may contain different internal components [e.g.,
deoxyribonucleic acid (DNA), organelles] and do not present
prothrombotic activity despite displaying PS (Jimenez et al., 2003;
Hristov et al., 2004). They present a density of 1.24–1.28 g/mL
and their role is still not clear. Apoptotic bodies might be an
easier system for cellular clearance themselves due to small size
or, alternatively, an active signal to promote cellular clearance of
the remaining damaged cells (Wickman et al., 2013).
Platelet-Derived Microvesicle Release
and Clearance
Platelet-derived microvesicles represent about 70–90% of all
circulating MV pool and contribute to many biological processes
(Berckmans et al., 2001; Aatonen et al., 2012). pMVs are elevated
in peripheral blood as a result of chronic platelet activation
in various disease states (Tan et al., 2005). Exposure of native
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blood to very high shear rate increases platelet expression
of GPIIb/IIIa, rendering the platelet membrane procoagulant
and also stimulating pMV formation (Sakariassen et al., 1998).
Indeed, previous studies with patients with genetic defects have
shown that impaired platelet PCA is translated into reduced
vesicle formation (Sims et al., 1989; Gemmell et al., 1993).
Despite the mechanisms by which MVs are formed are not well-
known yet, pMVs are specifically shed from the platelet plasma
membrane by an exocytic budding process (Holme et al., 1993),
which involves increases in intracellular calcium, cytoskeleton
reorganization (Yano et al., 1994; Pasquet et al., 1996) and changes
in membrane lipid asymmetry, and is triggered by physical
stimuli (shear stress, hypoxia) (Gemmell et al., 1993; Takano
et al., 2004), by a variety of specific agonists (in an additive or
even synergistic way; Xiao et al., 2002) or by platelet prolonged
storage without agonist/stimuli requirement (Owens, 1994).
While most non-physiologic agonists like calcium ionophore
are the most potent inducers of MVs, the order of potency
of physiologic agonists is C5b-9 membrane attack complex
>thrombin plus collagen >thrombin >collagen >adenosine
diphosphate >epinephrine (Connor et al., 2010). Other platelet
stimuli are proinflammatory mediators [like lipopolysaccharide
(Stahl et al., 2011), cytokines (Nomura et al., 2000), and
soluble CD40 ligand (Prasad et al., 2003)], PAR agonists (Chung
et al., 2004), thrombin receptor activating peptide (Tschuor
et al., 2008), and prolyl gallate (Xiao et al., 2002), among
others. Regarding ADP, the P2Y12 receptor contributes to pMV
formation from activated platelet surfaces without any significant
involvement of the P2Y1 receptor (Kahner et al., 2008).
Clearance of pMVs remains unknown. In contrast to platelets
that have a life span of about 10 days, pMV half-life is about
30 min in mice (Flaumenhaft, 2006), or even less than 10 min
in rabbits (Rand et al., 2006). In other circumstances, such as
insertion of material test segments to a shunt in canines, pMV
clearance is delayed to a 3–24 h period following removal of
test segment from the shunt (Gemmell et al., 1997). Recently,
aphaeresis-derived pMVs were shown to circulate for more
than 5 h (Rank et al., 2010), increasing the discrepancy in
pMV turnover, which may rely on distinct fate signals due to
secretion process (Dasgupta et al., 2009; Abdel-Monem et al.,
2010). Indeed, levels of pMVs might reflect the balance between
dynamic mechanisms for release and clearance (Ayers et al.,
2015).
PLATELET-DERIVED MICROVESICLES
Platelet-derived microvesicles retain certain parental cell
characteristics, such as surface receptors, although their content
depends on platelet stimuli, giving differences in their phenotype
(Sims et al., 1989; Montoro-Garcia et al., 2014). pMV protein
content is highly dependent on the type of physiological agonists
involved in platelet stimulation (Milioli et al., 2015). MVs were
shown to differ in content between human samples and between
MV size classes (Dean et al., 2009; Bastos-Amador et al., 2012).
Regarding phospholipid MV content, the relative abundance
of lyso-phosphatidylcholines among other phospholipid
classes (phosphatidylcholines, lyso-phosphatidylethanolamines,
PSs, phosphatidylinositols, sphingomyelins, and diacyl- and
plasme(a)nyl-phosphatidylethanolamines) was found to
be significantly higher in blood MVs than platelets and
platelet-derived MVs (Losito et al., 2015). In terms of protein
composition, pMVs from activated platelets are highly enriched
in α-granule-derived factor Va and Xa (Monkovic and Tracy,
1990) and thus possess procoagulant properties (Connor et al.,
2009). Despite their heterogeneity (Perez-Pujol et al., 2007) a
high percentage of pMVs express surface activation markers
such as glycoprotein (GP)-Ibα (CD42b), P-selectin (CD62P),
β3-integrin (GPIIIa, CD61), αIIb-integrin (GPIIb, CD41),
lysosomal-associated membrane protein-3 (LAMP3, CD63), and
thrombospondin-1 (TSP-1). However, healthy individuals
may also have CD41+/CD61+/PS+-MVs derived from
megakaryocytes instead of activated platelets. Megakaryocyte-
derived MVs differ from pMVs in that they do not express
granule fusion markers (CD62P−, LAMP-1−) and only contain
full-length filamin A (Flaumenhaft et al., 2009). pMVs carry
as well other platelet proteins such as platelet activating
factor (PAF), β-amyloid precursor, anticoagulant protein C/S,
complement C56b-9, and the chemokines CXCR4, CXCL4,
CXCL7, and CCL5, which may exert potent biological effects
in recipient cells of the circulation (Garcia et al., 2005). Indeed,
pMVs were able to transfer fully operational surface receptors,
such as CSCR4 and CD41, onto the recipient cells (Rozmyslowicz
et al., 2003). pMVs thereby might modulate platelet, leukocyte,
and vascular endothelial cells (EC) function, by modulating
monocyte-EC interactions (Barry et al., 1998) and inducing
chemotaxis (Barry et al., 1999). Because pMVs circulate in the
blood flow, they could serve as shuttle modules and signaling
transducers not only to neighboring cells (local environment)
but also to cells at relative distance from their cell or site of
origin, triggering cell activation, phenotypic modification,
and reprogrammation of cell function, complementing the
well-known processes of intercellular communication. How
MVs are selectively released and targeted to exert their various
pathophysiological functions remains unknown.
PLATELET-DERIVED MICROVESICLES
AND CARDIOVASCULAR DISEASE
Plasma levels of circulating MVs are known to increase with the
presence of cardiovascular risk factors [hypercholesterolemia
(Suades et al., 2014), obesity (Murakami et al., 2007),
hypertension (Preston et al., 2003), diabetes mellitus (DM;
Sabatier et al., 2002; Zhang et al., 2013), metabolic syndrome
(Helal et al., 2011), sleep apnea (Trzepizur et al., 2014), and
progression of atherosclerosis (Nomura et al., 1995; Ueba et al.,
2008)]. Within DM, type-1 DM patients had twice tissue factor
(TF)-positive pMVs than type-2 DM patients (Chiva-Blanch
et al., 2016d). Likewise, elevated pMVs are associated with the
10-year CVD risk score (Ueba et al., 2010) and with age (van
der Zee et al., 2006) in healthy men. Indeed, total number
of pMVs was significantly greater in women than men in a
population of healthy individuals (Gustafson et al., 2015). During
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past decades, the involvement and importance of the immune
system and inflammation in the initiation and progression of
atherothrombosis has become clear, also contributing to CVD
risk. Raised levels of circulating pMVs have been detected
in young women with polycystic ovary syndrome (Willis
et al., 2014), in patients with rheumatoid arthritis in which
pMVs express CLEC-2 (Gitz et al., 2014) and in patients with
antiphospholipid antibodies in which pMVs correlate with
anti-β2-GP (Chaturvedi et al., 2015). Additionally, elevated levels
of circulating pMVs contribute to the increase PCA in patients
with oral cancer (Ren et al., 2015).
High concentrations of circulating pMV (ranging from
∼3,000–11,000/µL) have been reported in patients with CHD
including ACS (Michelsen et al., 2008; Bulut et al., 2009; Biasucci
et al., 2012; Cui et al., 2013; George et al., 2015). In addition,
circulating pMVs have been reported to reflect the size of
myocardium at risk in patients with ST-elevation myocardial
infarction (Jung et al., 2012) and correlated with the presence
of atherothrombotic lesions in carotid plaques (Lukasik et al.,
2013), intracranial atherosclerotic lesions (Kuriyama et al., 2010),
early stage of coronary artery calcification in menopausal women
(Jayachandran et al., 2008), cerebrovascular disease (Chiva-
Blanch et al., 2016b) and peripheral arterial disease (van der
Zee et al., 2006). Stenting in stable coronary atherosclerotic
lesions is associated with a substantial release of pMVs (Horn
et al., 2015). Interestingly, the link with increased circulating
pMV levels is more consistent with coronary artery disease
patients than in those with chronic kidney disease (Chen
et al., 2014). Indeed, overproduction of pMVs and platelet
activation with suppressed aggregation may be even implicated
in the pathogenesis of coagulation abnormalities in children
with congenital heart disease (Horigome et al., 2002; Ismail
and Youssef, 2012). Recently, pMVs have been point out as
biomarker of the vaso-occlusive phenotype-related severity in
sickle cell anemia (Nebor et al., 2014). Furthermore, pMVs seem
to be involved in the development of disseminated intravascular
coagulopathy in critically ill patients but are not related to
hospital mortality, while pMV/platelet ratio is independently
associated to hospital mortality (Ohuchi et al., 2015). Finally,
total pMVs were lower while activated platelet-derived MVs (P-
Sel+) were higher in preeclampsia than in healthy women, being
involved in the hypercoagulable intravascular reaction during
pregnancies complicated by preeclampsia (Campello et al., 2015).
Therefore, pMV may reflect the severity of the endothelial injury
and platelet activation during thrombotic events (Tan et al., 2005;
Jung et al., 2012).
Acquiring knowledge about the role of pMVs in CVD might
also have implications for treatment. Caution must be taken when
considering cMVs as pathological markers, since medical therapy
with pharmacological agents can affect MV release during disease
progression (Mobarrez et al., 2011; Nomura et al., 2011). Thus,
pMVs are susceptible targets for pharmacological modulation
and offer new options for therapies specifically focused on
lowering MV levels. For instance, anti-platelets drugs such as
GPIIb/IIIa inhibitors (Goto et al., 2003; Morel et al., 2004),
acetilsalicilic acid (Bulut et al., 2011), and clopidogrel (Judge
et al., 2010; Franca et al., 2012), and the anti-diabetic drug
ticlopidine (Nomura et al., 2004c) have shown to reduce pMVs.
In patients under antithrombotic treatment, pMVs exposing
CD62P or CD142 are still elevated 6 months after initiation of
the therapy (Skeppholm et al., 2012), possibly due to the fact
that low-dose of acetilsalicilic acid might not be strong enough to
suppress shedding of pMVs into the microcirculation (Lubsczyk
et al., 2010). Our group has reported that aspirin intake in diabetic
patients has no effect on pMVs (Chiva-Blanch et al., 2016d).
However, statins as the cornerstone drug therapy for lipid-
lowering decrease pMVs in patients with different cardiovascular
risk factors. Thus, simvastatin and pravastatin decreased pMVs
in patients with hypertension (Nomura et al., 2004a) and type-2
diabetes (Nomura et al., 2004b; Sommeijer et al., 2005). Similarly,
atorvastatin reduces thrombin generation and expression of TF,
GPIIIa, and CD62P on pMVs in patients with peripheral vascular
disease (Mobarrez et al., 2011) and with type-1 diabetes and
dyslipidemia (Tehrani et al., 2010). In a recent study aimed
to evaluate the effects of lipid-lowering treatment on cMV
generation in patients in primary prevention of atherosclerosis,
we have demonstrated that, in hypercholesterolemic patients,
statin treatment reduces not only the number of pMVs but
markers of activated platelets, activated inflammatory cells and
TF with respect to untreated subjects even when LDL levels
were similar (Suades et al., 2013). In agreement, stroke patients
with hyperlipidemia presented a significantly lower percentage
of pMVs compared to control subjects, not only due to lipid-
lowering but also because of a significant role in reduction of
platelet activation and reactivity (Pawelczyk et al., 2015). Hence,
in view of all these data statins may exert beneficial effects by
inhibiting microvesicle generation and the triggering of MV-
dependent mechanisms. Other cardioprotective agents that have
an impact on pMV levels include calcium channel blockers
(Nomura et al., 2005a,b), antioxidants such as vitamin C (Morel
et al., 2003), and PPAR-pan agonists like bezafibrate (Kagawa
et al., 2001). As several therapeutic drugs seem to influence the
levels and composition of pMVs, the lowering of pMV load in the
circulation might prove, at least in part, to be a novel therapeutic
strategy for treatment. Nevertheless, whether the beneficial effect
of a pharmacological approach is associated to pMV reduction
and to a clinical improvement needs to be fully demonstrated.
In addition to pharmacological modulation, the therapeutic
potential of progenitor cell-derived microvesicles is promising
since they are naturally occurring, efficient, therapeutic delivery
vehicle that might be used to deliver drugs to specific targets.
Furthermore, the therapeutic potential of MVs has also been
pointed out by the use of synthetic MVs, mimicking natural ones.
MVs could have a broad potential in several conditions from
inflammation to MI (Getts et al., 2014). Further characterization
of the biological effects of these MVs is warranted.
PLATELET-DERIVED MICROVESICLES IN
ATHEROINFLAMMATION AND
ATHEROTHROMBOSIS
Platelets are not only key mediators of thrombosis but also of
inflammation by directly interacting with cells of the immune
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system (Fuentes et al., 2013). Reports in the last decade have
described the secretion by platelets of proinflammatory molecules
that exacerbate the inflammatory response in atherosclerotic
lesions, during the initial injury to the endothelium as well
as in the later stages when the atherosclerotic plaque is
destabilized (von Hundelshausen and Weber, 2007). In addition
to their pivotal role in CVD event presentation, platelet-derived
MVs participate in inflammatory responses because they carry
immune complexes, which are highly proinflammatory (Boilard
et al., 2010; Cloutier et al., 2013). High-shear-stress-induced
pMVs in a cone-plate viscometer device in vitro enhance
expression of inflammatory cytokines either in ECs or in the
human monocytic THP1-cell line (Nomura et al., 2001). Of
note, pMVs may have a role in initial stages of atherosclerotic
process, as they can facilitate cell-to-cell communication and
adhesion processes between blood and vessel wall (Mause et al.,
2005). pMVs could also play part in atherogenesis by enhancing
proliferation of vascular smooth muscle cells (SMCs) as well
as EC and chemotaxis and proliferation of hematopoietic cells
(Miyazono et al., 1985; Weber et al., 2000; Baj-Krzyworzeka
et al., 2002; Pakala, 2004). These results clearly suggest that
pMVs contribute to atherosclerosis development and to vascular
damage occurring in inflammatory disorders (Nomura et al.,
2001; Inoue et al., 2006; Suades et al., 2015b). To this respect,
Csongrádi et al. (2011) have described that blood pMV levels
positively associate with abnormal carotid IMT and other
risk factors in obesity suggesting a critical role of enhanced
platelet reactivity in atherosclerotic wall alteration. In addition
to pMVs, circulating lymphocyte-derived CD45+/CD3+-MVs
have recently been shown to be biomarkers of asymptomatic
subclinical lipid-rich atherosclerotic plaques in patients with
familial hypercholesterolemia (Suades et al., 2014), and CD11b+-
LMV of unstable plaques in asymptomatic patients with high-
grade carotid stenosis (Sarlon-Bartoli et al., 2013). Indeed,
CD45+/CD3+-lymphocyte-derived MVs were found increased
in individuals at high cardiovascular risk (HCVR) who were
about to develop a major CVE (Chiva-Blanch et al., 2016c).
In a similar fashion, levels of pMVs were significantly
higher in patients with intermediate coronary lesions compared
to subjects with normal coronary arteries (Chou et al.,
2014). Progression of early atherosclerotic lesions to advanced
plaques and their thrombotic complications are consequence
of complex interactions between blood cells and arterial vessel
wall components (Badimon and Vilahur, 2014). Erosion, fissure,
or rupture of the atherosclerotic plaques are triggering events
in ACS, being platelets a key player in these atherothrombotic
processes (Fuster et al., 1990). We have found that HCVR
patients have significantly high shedding of cMVs carrying
epitopes of platelet activation and directly associate to lipid-
rich subclinical atherosclerotic burden (Suades et al., 2015a).
Besides, these prothrombotic pMVs have demonstrated an
incremental prognostic value beyond the classical risk factor
model for the prediction of cardiovascular risk, indicating that
the state of activation of platelets in the blood-vascular interface
may increase the release of pMVs that become markers of
the high atherothrombotic risk (Suades et al., 2015a). Blood
thrombogenicity can be partially explained by the fact that
TF is not only present in the subendothelium, but also in
the circulation (Sambola et al., 2003). TF is associated with
monocytes, platelets, and even microvesicles, the latter represent
an important source of the so-called blood-borne TF. We have
also detected higher numbers of TF-positive MVs derived from
platelets in HCVR patients; thus, pMV-associated TF might
contribute to atherothrombosis. In the same line, our group has
reported that clustering the information provided by TF+-pMVs,
eMVs, and LMVs might predict CVEs in high-risk patients
following a Mediterranean diet supplemented with nuts (Chiva-
Blanch et al., 2016a).
Besides a potential relevance of MVs and pMVs as markers
of subclinical atherosclerosis with a critical importance in
reclassification of asymptomatic subjects, the follow-up study
performed by Namba et al. (2007) in patients with a first ACS
points to the fact that high pMV levels at discharge may also
be an independent predictor for secondary thrombotic events
and poorer clinical outcomes at 1 year. This study stresses the
usefulness of pMV levels to differentiate patients who develop
secondary atherothrombotic events from patients who develop a
stable phenotype after a first ACS (Namba et al., 2007).
As pre- and analytical methodological procedures (Aatonen
et al., 2014; Eckstein et al., 2014; out of the scope of this review)
are still under assessment, care should be taken when expanding
findings to prospective clinical studies. Prior to large-scaling, it
would be desirable a complete international standardization of
cMVs analysis.
Further to their potential as biomarkers of cell activation,
increasing evidence support the concept that pMVs are causal
inducers of atherosclerosis progression and thrombosis. MVs
from human atherosclerotic plaques are highly abundant and
more thrombogenic than plasma MVs, with differences between
LMVs and pMVs (Leroyer et al., 2007). Ramacciotti et al. (2009)
using a model of venous thrombosis, provided evidence that
thrombus weight correlated negatively with LMVs and positively
with pMVs. Besides, levels of pMVs have been found to be higher
in culprit coronary arteries than in peripheral arteries of STEMI
patients (Suades et al., 2016). In this microenvironment, pMVs
released by activated platelets may provide a new prothrombotic
interface for fibrin formation between the circulating blood and
the growing thrombus (Ando et al., 2002), since they are able
to interact with fibrin (Siljander et al., 1996). Thus, it has been
proposed that pMVs might play a key role in vivo causing
thrombotic events, even without the direct involvement of
platelets (Oberle et al., 2007). The response to this hypothesis was
provided by demonstrating that pMVs, beyond being biomarkers
of cell activation, have functional effects on cardiovascular
atherothrombotic disease because they enhance platelet and
fibrin deposition on atherosclerotic arterial wall (Suades et al.,
2012). This proof of principle study was performed perfusing
atherosclerotic vessel wall with blood with/without exogenously
added pMVs and showed that high pMVs concentration was able
to induce more platelet and fibrin deposition (Figure 1) (Suades
et al., 2012; Mause, 2013). We have also found a decrease of
pMVs with surface markers of adhesion and activation in the
post-thrombus blood after perfusing the exposed thrombogenic
surfaces and in STEMI-patients (Suades et al., 2015c). Therefore,
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FIGURE 1 | Platelet-derived microvesicles (pMVs) in human blood enhance thrombosis on atherosclerotic plaques. (A) Effects of pMVs on platelet
deposition were assessed under controlled flow conditions exposing damaged arterial wall in the Badimon perfusion chamber to human blood
immunohistofluorescence (IHF). (B) Platelet deposition on human atherosclerotic vessel wall was significantly increased in pMV-enriched bloods (6,000/µl).
Specifically, pMVs also induced increase in platelet (P < 0.05) and fibrin (P < 0.05) deposition on human atherosclerotic arteries. (C) Immunofluorescence staining
clearly showed the effects of adding pMVs to normal blood both in platelet and fibrinogen deposition. Representative immunophotographs of perfused human
atherosclerotic substrates: platelet (green) and fibrin (red) deposition on human atherosclerotic vessels at a shear rate condition of 1,680 s−1 of whole blood and of
whole blood with 6,000 pMVs/µl. Scale bar is 25 µm. Therefore, an increased content of pMVs, even in normal blood conditions, enhance platelet deposition, and
thrombus formation.
our data reinforce pMVs in blood promotes platelet adhesion
due to a high tendency to adhere, as previously reported
(Forlow et al., 2000) and support their clear implication in
the atherothrombotic process. Altogether, this growing body
of evidence support the view that pMV dissemination and
exposure of their procoagulant membrane to the extracellular
matrix (Merten et al., 1999) at the site of endothelial injury or
onto the forming fibrin (Siljander et al., 1996) may serve as an
adhesion surface on adhered platelets and within the thrombus to
enable thrombin generation and to further support recruitment
of platelets (Suades et al., 2012) and leukocytes (Mause et al.,
2005) stimulating platelet aggregation (Berckmans et al., 2001;
Nomura et al., 2001; Raturi et al., 2008).
MOLECULAR AND CELLULAR
MECHANISMS RELATING pMVs WITH
ATHEROSCLEROSIS PROGRESSION
AND THROMBUS FORMATION
As described above, pMVs are considered to be both biomarkers
and effectors of cell signaling. Importantly, circulating MVs can
mediate communication between vascular cells because they
allow membrane interactions between cells at distance (Meziani
et al., 2008). Elucidation of the molecular mechanisms by
which MVs might evoke and promote vascular inflammation,
atherosclerosis plaque progression, and thrombus formation
(Figure 2) is crucial for improving our understanding of their
role in health and disease. Hereby, we present a compilation
of functional studies investigating the underlying pMV-driven
molecular processes in atherothrombosis by using either in vitro,
in vivo, or ex vivo models (Table 1):
Platelet-Derived Microvesicles and
Endothelial Dysfunction
Platelet-derived microvesicles pMVs interact with activated ECs
and recruit activated platelets to injured subendothelium (Merten
et al., 1999). T lymphocytes are recruited in the atherosclerotic
lesion and an immunomodulatory role of pMVs on T cells
has been recently described (Sadallah et al., 2014). pMVs
carry a concentrated CD40L signal, induce polymorphonuclear
leukocyte-damage of human pulmonary microvascular ECs and
may affect the development of transfusion-related acute lung
injury (Xie et al., 2015). Since MVs from platelets contain active
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FIGURE 2 | Platelet-derived microvesicles promote vascular inflammation, atherosclerosis plaque progression, and thrombus formation. Schematic
representation of the molecular mechanisms by which MVs evoke atherothrombotic-related processes: endothelial dysfunction, proinflammatory reactions,
procoagulant and prothrombotic effects, and neovascularization.
executive caspase-3, they have also been involved in apoptosis
(Boing et al., 2008).
Platelet-Derived Microvesicles and
Proinflammatory Activity
Platelet-derived microvesicle seem to be proinflammatory mainly
through activating ECs (Merten et al., 1999) and enhancing
cytokine responses (Barry et al., 1998). Thus, Barry et al. (1998),
based on in vitro cell culture studies, described that pMVs
activate ECs and monocytes, which results in increased adherence
between both cell types. The effect of pMVs may relay in their
content of unmetabolized AA and involve activation of PKC. Part
of the proinflammatory and proatherogenic potential of pMVs
has been related to their capacity to act as a transcellular delivery
system for chemokines such as RANTES (CCL5) on activated
vascular endothelium (outside-in signaling mechanism involving
GP-IIb/IIIa and junctional adhesion molecule-A) triggering
monocyte adhesion into early atherosclerotic lesions (Mause
et al., 2005). Thus, MVs from stimulated platelets that are
able to activate monocytes through RANTES, in turn facilitate
monocyte migration, tissue recruitment and differentiation
toward macrophage (Vasina et al., 2011).
In addition, pMVs promote expression of Von Willebrand
factor (vWF) at the EC surface (involving anionic phospholipids,
lactadherin, and GPIIb/IIIa) and the subsequent platelet/EC
interaction under flow (Terrisse et al., 2010). pMVs also induce
the expression of cyclooxygenase (COX)-2, but not COX-1 (Barry
et al., 1997). Moreover, upon platelet activation and in response to
lipopolysaccharide stimulation (TLR4/JNK/Akt pathway; Brown
and McIntyre, 2011), a portion of IL-1β is shed in its mature
form in pMVs and stimulates the adhesiveness of human ECs to
leukocytes (Lindemann et al., 2001).
Other studies have shown that pMVs are also carriers of PAF
(Iwamoto et al., 1996; Mitsios et al., 2006). Its presence in pMVs
plays an important role in cell-to-cell interactions, as observed in
models of acute and chronic inflammation (Mitsios et al., 2006).
In this context, PAF production may be of great importance in
coronary atherothrombosis and in the inflammatory response
elicited during intracoronary injury induced by angioplasty
(Goudevenos et al., 2001).
Interestingly, pMVs can also affect leukocyte aggregation and
recruitment by direct interactions mediated by P-Selectin/PSGL-
1-dependent interactions under flow conditions, especially in
diseases where the concentration of the particles is elevated
(Forlow et al., 2000), as well as Mac-1 (Inoue et al., 2008). In this
regard, pMV binding to neutrophils can also increase neutrophil
aggregation and phagocytic activity (Jy et al., 1995) and pMVs
trigger monocytic cell aggregation and release of procoagulant
TF-expressing MVs in vitro (Lin et al., 2015). In addition to pMV-
mechanisms leading to inflammatory response, MVs released
from thrombin-stimulated platelets to the extracellular space
might contain mitochondria, which are able to interact with
neutrophils triggering their adhesion to the endothelial wall
(Boudreau et al., 2014). Additionally, pMVs from thrombin-
activated platelets expressed CD40L and enhanced monocyte-
derived dendritic cell maturation leading to the activation of T
cells (Kaneider et al., 2003).
However, there are also conflicting reports in the scientific
literature. pMVs inhibit IL-17 and IFN-γ production by
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TABLE 1 | Type of studies investigating the molecular mechanisms implicated in the effects of platelet-derived microvesicles in atherosclerosis
progression and thrombus formation.
In vitro models In vivo models Ex vivo models
Endothelial dysfunction Boing et al., 2008
Merten et al., 1999
Sadallah et al., 2011
Xie et al., 2015
Merten et al., 1999 Boing et al., 2008
Neovascularization in atherosclerotic plaques Battinelli et al., 2011
Brill et al., 2005
Italiano et al., 2008
Kim et al., 2004
Mause et al., 2010
Prokopi et al., 2009
Shai et al., 2012
Brill et al., 2005
Hayon et al., 2012
Ma et al., 2015
Mause et al., 2010
Ohtsuka et al., 2013
Shan et al., 2013
Varon et al., 2012
Ohtsuka et al., 2013
Proinflammatory activity Baj-Krzyworzeka et al., 2002
Barry et al., 1997
Barry et al., 1998
Boudreau et al., 2014
Boilard et al., 2010
Brown and McIntyre, 2011
Brunetti et al., 2000
Cloutier et al., 2013
Dinkla et al., 2016
Forlow et al., 2000
Garcia et al., 2005
Inoue et al., 2008
Iwamoto et al., 1996
Jy et al., 1995
Kaneider et al., 2003
Lin et al., 2015
Lindemann et al., 2001
Mause et al., 2005
Mitsios et al., 2006
Miyazono et al., 1985
Nomura et al., 2001
Pakala, 2004
Ray et al., 2008
Sadallah et al., 2011
Setzer et al., 2006
Terrisse et al., 2010
Vasina et al., 2011
Vasina et al., 2013
Weber et al., 2000
Merten et al., 1999 Chiva-Blanch et al., 2016c
Chou et al., 2014
Dinkla et al., 2016
Inoue et al., 2006
Inoue et al., 2008
Mause et al., 2005
Mitsios et al., 2006
Nomura et al., 2001
Sarlon-Bartoli et al., 2013
Suades et al., 2014
Suades et al., 2015b
Proacoagulant activity Aleman et al., 2011
Berckmans et al., 2001
Butenas et al., 2005
Camera et al., 2010
Escolar et al., 2008
Forlow et al., 2000
Miyazaki et al., 1996
Gilbert et al., 1991
Lopez-Vilchez et al., 2007
Lösche et al., 2004
Raturi et al., 2008
Reininger et al., 2006
Sinauridze et al., 2007
Siljander et al., 1996
Suades et al., 2012
Suades et al., 2015c
Tans et al., 1991
Chou et al., 2004
Oberle et al., 2007
Ramacciotti et al., 2009
Ando et al., 2002
Berckmans et al., 2001
Chiva-Blanch et al., 2016a
Chung et al., 2007
Csongrádi et al., 2011
Hugel et al., 1999
Lopez-Vilchez et al., 2012
Namba et al., 2007
Raturi et al., 2008
Suades et al., 2015a
Suades et al., 2015c
Suades et al., 2016
Windelov et al., 2014
Neovascularization in atherosclerotic plaques Battinelli et al., 2011
Brill et al., 2005
Brill et al., 2005
Hayon et al., 2012
Ohtsuka et al., 2013
(Continued)
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TABLE 1 | Continued
In vitro models In vivo models Ex vivo models
Italiano et al., 2008
Kim et al., 2004
Mause et al., 2010
Prokopi et al., 2009
Shai et al., 2012
Ma et al., 2015
Mause et al., 2010
Ohtsuka et al., 2013
Shan et al., 2013
Varon et al., 2012
regulatory T cells through P-selectin (Dinkla et al., 2016).
pMVs also show inhibitory properties on macrophage and DC
differentiation (Sadallah et al., 2011), emphasizing the concept of
selective packaging of MV cargo dependent on platelet stimulus
and the need to advance pMV characterization in future studies.
Thus, pMVs actively take part in the immune response regulation
at sites of vascular inflammation, where they are known to adhere
and interact with leukocytes, promoting the healing process.
Furthermore, several lines of recent evidence support the
concept that pMVs contain several miRNAs which may facilitate
the communication between platelets with inflammatory cells
(Gatsiou et al., 2012). For further details on this issue, please refer
to review from Hulsmans and Holvoet (2013). All these crosstalk
interactions are important for the propagation of inflammation
at the site of vascular injury, as well as for sustaining thrombus
growth (Santos-Gallego et al., 2014).
Finally, pMVs contain transcription factors, such as
PPARγ, derived from parent cells (Ray et al., 2008). And
proteomic analysis has led to the discovery of three other
transcription factors in pMVs: RuvB-like 2, STAT3, and
STAT5A (Garcia et al., 2005). pMV signaling induces differential
expression of inflammation-relevant genes in monocytes,
which represents a novel link between homeostasis and
inflammation (Setzer et al., 2006). Besides, pMVs formed
by aging platelets in an apoptotic-like process (Vasina et al.,
2011) promote differentiation of monocytes to a resident
CD14+/CD36+/CD68+-macrophage phenotype. These
macrophage-like cells release metalloproteinases and H2O2
that contribute to plaque destabilization and eventual rupture, a
clinically precipitating event in atherosclerotic disease (Vasina
et al., 2013). Moreover, pMVs have shown to inhibit apoptosis of
polymorphonuclear leukocytes (Brunetti et al., 2000). Therefore,
specific bioactive pMV cargoes of miRNAs as well as of lipids
and proteins might offer novel pharmacological targets for
atherothrombosis therapy applicable in each stage of disease.
Platelet-Derived Microvesicles and
Procoagulant Activity
Although pMVs can express both procoagulant (Miyazaki et al.,
1996) and anticoagulant proteins (Tans et al., 1991), a key feature
of pMV is their procoagulant potential. High shear-stress rates
and immobilized vWF on the luminal surface of an obstructing
atherosclerotic plaque can trigger the generation of procoagulant
MV via platelet GPIbα-vWF interactions (Reininger et al.,
2006). Through membrane transverse migration and surface
exposure of anionic phospholipids including PS, platelets release
PS+-pMV that possess high affinity binding sites for activated
coagulation factors such as factor IXa, Va, Xa, and VIII
and provides a catalytic environment optimal for subsequent
thrombin formation (Gilbert et al., 1991; Chou et al., 2004).
Sinauridze et al. (2007), by comparing procoagulant properties
of A23187-calcium ionophore-activated platelets and pMVs
using several in vitro models of haemostasis, have provided
evidence that pMV surface is approximately 50- to 100-fold
more procoagulant than activated platelet surface. Low levels of
procoagulant PS-positive pMVs are associated with impaired clot
formation in trauma patients and may play an important role in
trauma-associated coagulopathy (Windelov et al., 2014).
Another molecular property that conveys PCA to pMV is
functional TF. As stated, the cellular origin of blood-borne TF is
unresolved. LMV seem to display the most relevant amount of TF,
the most important initiator of intravascular thrombin and fibrin
formation (Lösche et al., 2004). Although TF cell origin is still
controversial (Butenas et al., 2005), today is generally accepted
that platelets carry and transfer TF (Camera et al., 2010) and
also possess mechanisms to internalize TF-rich MVs (Escolar
et al., 2008), and that platelet-associated TF enhances platelet
reactivity and thrombin generation with flowing blood (Lopez-
Vilchez et al., 2012). Increased TF-positive procoagulant MVs are
present in the circulating blood of patients under pathological
conditions (Hugel et al., 1999) and are taken up by platelets
inducing aggregation in the presence of factor VII (Lopez-
Vilchez et al., 2007). According to Lösche et al. (2004), pMV
transfer TF to monocytes but not to neutrophils. In fact, in vivo
appearance of TF-bearing pMV on leukocytes in pericardial
blood during cardiac surgery has been reported (Chung et al.,
2007). Other studies, however, describe a lack of TF in pMV
because it is not packed in the platelet-derived MV during platelet
activation (Aleman et al., 2011). This latter finding arise the
concept that MV derived from monocytes and platelets exhibit
unique PCA and differentially modulate clot formation, structure
and stability. According to this hypothesis, monocyte-derived
MV would initiate the extrinsic pathway whereas pMV would
augment thrombin generation and promote clot propagation
following TF- or contact-initiated clotting (Aleman et al., 2011).
Further studies on in vivo thrombosis models are necessary to
investigate the contribution of MVs from different parent cells to
the thrombotic process.
Platelet-Derived Microvesicles and
Neovascularization in Atherosclerotic
Plaques
A key factor in the evolution of subclinical atherosclerosis to an
ischemic event is the increased vulnerability of atherosclerotic
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plaques. It is not known why some of the existing plaques in
the arterial tree rupture and trigger thrombotic complications
while some others do not. Human coronary plaques associated
to ACS show the highest accumulation of neovessels (Juan-
Babot et al., 2003). Increasing evidence shows that high
density of neovessels in coronary atherosclerotic lesions is
associated with hemorrhagic leaky vessels, unstable plaques,
and high rate of thrombotic episodes (McCarthy et al., 1999).
During plaque development pro-angiogenic pathways seem
to be re-activated leading to formation of immature blood
vessels prone to rupture. Infiltration of microvessels into the
media, intima, and plaques, originates predominantly from
proliferating vasa vasorum although recent work has also
signaled toward bone marrow-derived circulating endothelial
progenitor cells (EPC; Kawamoto et al., 2003). pMVs have
shown to promote angiogenesis in a number of studies
(Kim et al., 2004; Brill et al., 2005; Mause et al., 2010).
In vitro cell culture studies provide evidence that pMV
promote cell proliferation and survival, migration, and tube
formation in human umbilical vein EC via GPCR and kinase
signaling pathways (Kim et al., 2004). Similarly, pMV augment
the adhesion and neovascularization capacities of circulating
angiogenic cells obtained from atherosclerotic patients through
a RANTES-mediated mechanism (Ohtsuka et al., 2013). pMVs
induce sprouting both in vivo and in vitro (Brill et al.,
2005) and influence the angiogenic activity of EPC (Prokopi
et al., 2009). pMV-induced invasion of ECs through a layer
of matrigel was mediated by vascular endothelial growth
factor, heparanase, and platelet-derived growth factor, but not
by basic fibroblast growth factor (Brill et al., 2005). Both
Dok-2 and CD49f proteins participate in the mechanisms
that regulate angiogenesis and, interestingly, are shown to
be again differentially regulated in pMV depending on the
platelet stimulus (Shai et al., 2012). These data are in line
with the studies that show a differential localization of
angiogenic cytokines in different platelet granules (Italiano
et al., 2008) and that the release of angiogenic regulatory
proteins is modulated by physiological processes (Battinelli
et al., 2011), indicating by which mechanism operate the
pro-angiogenic effect of pMVs. In a stroke model, a local
delivery of pMV to the lateral ventricles induces angiogenesis,
neurogenesis, and neuroprotection and reduces behavioral
deficits after brain ischemia (Hayon et al., 2012; Varon et al.,
2012).
Thus, in pathological states such as subclinical advanced
atherosclerosis, pMV shed from the circulating platelets
may reach adequate concentrations and that elevated
levels of pMV could contribute to plaque development
and instability. In a distinct scenario, pMVs could also
collaborate with the remote conditioning protective
effect against ischemic-reperfusion injury in a model of
cerebral infarction, likely by exerting similar angiogenic
properties (Shan et al., 2013). Indeed, ischemia-reperfusion
preconditioning induces an increase in pMVs, which
confer at least part of the remote protective effect
against cardiac ischemic-reperfusion injury (Ma et al.,
2015).
EXOSOMES
Within EVs platelet-derived exosomes, first described by Heijnen
et al. (1999), have received increasing attention due to their
potential role as mediators of cell-to-cell communication. The
presence of exosomes containing miRNAs in circulating blood,
mainly derived from platelets, has emerged as a potential source
of biomarkers of CVD. Additionally, they have been implicated
in vascular and heart functions. Ago-miR-223 is delivered to EC
via microvesicles from activated platelets (Laffont et al., 2013) and
platelet-derived exosomes reduce ICAM-1 expression decreasing
monocyte adhesion (Gidlof et al., 2013) and induce EC apoptosis
(Janiszewski et al., 2004; Gambim et al., 2007). Thrombin-
stimulated platelet-derived exosomes, enriched in miR-223, miR-
339, and miR-21, inhibit PDGFR β expression in SMCs (Tan
et al., 2016). Moreover, exosomes may serve as effectors by which
damaged heart communicate for cardiac injury repair in the
setting of MI (Ottaviani et al., 2016). It is not clear so far whether
the intervention on exosome secretion processes during disease
would have therapeutic effects. However, in the next upcoming
years, study of exosomes molecular insights may help not only to
detect novel biomarkers of disease but also to provide potential
new therapeutic approaches for atherothrombotic cardiovascular
disease.
CONCLUSION AND PERSPECTIVES
Platelet-derived microvesicles may not only act as a biomarkers
of cell activation but also as important functional effectors that
linking inflammation, hypercoagulability and neovascularization
may contribute to the exacerbation of atherosclerotic lesion
growth and to ongoing thrombosis. Thus, pMVs are emerging
as novel and specific pharmacological targets to manage
atherothrombosis and, additionally as potential therapeutic
tools for drug delivery, cardioprotection, and regenerative and
personalized medicine. Although our understanding of pMVs has
considerably been expanded in the last decade, we are far from
completely understanding platelet microvesicle biology. In the
upcoming years, platelets and platelet-derived MV research will
likely advance and take a leading position in tackling down CVD.
Further studies are required to improve our knowledge
on the mechanisms underlying generation of circulating pMV,
from the characterization of the specific phenotype of released
pMVs by distinct stimuli and pathophysiological context, to
the identification of the complete composition and its influence
on other cells, and to the disentangling of molecular and
signaling processes involving pMVs as functional effectors in
atherosclerosis and atherothrombosis.
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